Publications by authors named "Klaus Podar"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

75

Total Likes

3

Extended Reach

75

Social Features

2
A
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia.
Stefanie Weiss, Bernhard Zdársky, Agnieszka Witalisz-Siepracka, Sophie Edtmayer, Anja Holzer, Kerstin Heindl, Emilio Casanova, Klaus Podar, Dagmar Stoiber

Cancer Lett· March 2025

Videos about Article: user

1 1

View All Article and Social Media Activity
P
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Klaus Podar

Mol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP7 as a new target for activating anti-tumor immunity in cancer.
Katerina Popova, Johannes Benedum, Magdalena Engl, Carola Lütgendorf-Caucig, Piero Fossati, Klaus Podar

EMBO Mol Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy.
Rajeshwari Meli, Osman Aksoy, Sonia Vallet, Dea Slade, Klaus Podar

Expert Opin Ther Targets· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Teru Hideshima, Klaus Podar, Dharminder Chauhan, Kenji Ishitsuka, Constantine Mitsiades

Oncogene· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.
Judith Lind, Osman Aksoy, Michaela Prchal-Murphy, Fengjuan Fan, Mariateresa Fulciniti, Klaus Podar

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
Heinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, Siegfried Sormann, Martin Schreder, Klaus Podar

EJHaem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, Martin Schreder, Johannes Andel, Klaus Podar

Am J Hematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Tamara Gassner, Christina Chittilappilly, Theo Pirich, Benjamin Neuditschko, Klaus Hackner, Klaus Podar

J Immunother Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma.
Irene Strassl, Klaus Podar

Expert Opin Drug Discov· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage.
Yu-Tzu Tai, Gerrard Teoh, Boris Lin, Faith E Davies, Dharminder Chauhan, Klaus Podar

J Immunol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, Martin Sattler, Melissa Arn, Klaus Podar

Breast Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling.
Yu-Tzu Tai, Klaus Podar, Laurence Catley, Yu-Hua Tseng, Masaharu Akiyama

Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications.
Yu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, Renate Burger, Klaus Podar

Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting mtDAMPed macrophages for MM therapy.
Klaus Podar

Blood· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR).
Magdalena A Benda, Hanno Ulmer, Roman Weger, Patrick Reimann, Theresia Lang, Klaus Podar

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.
Osman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, Sonia Vallet, Klaus Podar

Cytokine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study.
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, Philipp Wohlfarth, Ulrich Jaeger

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Vincent Sunder-Plassmann, Osman Aksoy, Judith Lind, Martin Pecherstorfer, Sonia Vallet, Klaus Podar

Expert Opin Pharmacother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Klaus Podar

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
Klaus Podar, Xavier Leleu

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Klaus Podar

BMC Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Moshe Lapidot, Abigail E Case, Ellen L Weisberg, Chengcheng Meng, Sarah R Walker, Klaus Podar

Br J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients.
Josef Singer, Nguyen-Son Le, Daniel Mattes, Valerie Klamminger, Klaus Hackner, Klaus Podar

Cancers (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cachexia on bone turnover in cancer patients: a case-control study.
Hannes Zwickl, Elisabeth Zwickl-Traxler, Alexander Haushofer, Josef Seier, Klaus Podar

BMC Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis